{"organizations": [], "uuid": "c518a775aa2e7edfa468ec37f96bdec94c90fcfd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2015/02/04/102397115-121224922.1910x1000.jpg", "site_section": "", "section_title": "", "url": "https://www.cnbc.com/2018/02/06/gilead-shares-drop-after-hours-on-lower-q4-hepatitis-c-drug-sales.html", "country": "US", "domain_rank": 767, "title": "Gilead shares drop after hours on lower Q4 hepatitis C drug sales", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.059, "site_type": "news", "published": "2018-02-07T00:30:00.000+02:00", "replies_count": 0, "uuid": "c518a775aa2e7edfa468ec37f96bdec94c90fcfd"}, "author": "David Paul Morris", "url": "https://www.cnbc.com/2018/02/06/gilead-shares-drop-after-hours-on-lower-q4-hepatitis-c-drug-sales.html", "ord_in_thread": 0, "title": "Gilead shares drop after hours on lower Q4 hepatitis C drug sales", "locations": [], "entities": {"persons": [{"name": "gilead scienc", "sentiment": "negative"}], "locations": [{"name": "foster city", "sentiment": "none"}, {"name": "california", "sentiment": "none"}], "organizations": [{"name": "gilead", "sentiment": "negative"}, {"name": "pharmaceuticals gilead", "sentiment": "negative"}, {"name": "published updated moments ago reuters david paul morris | bloomberg", "sentiment": "none"}, {"name": "gilead sciences", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Gilead Sciences on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition and forecast a further slowdown next year, sending its shares lower after the closing bell.\nFor full-year 2018, the biotechnology company forecast product sales of $20 billion to $21 billion, down from $25.7 billion last year. The company also projected a 2018 tax rate of 21 percent to 23 percent.\nGilead, which last year paid nearly $12 billion for cancer immunotherapy company Kite Pharma, said it earned $1.78 a share in the fourth quarter after one-time items. Wall Street analysts, on average, had forecast $1.67 a share, according to Thomson Reuters I/B/E/S.\nIncluding a $6 billion income tax charge related to U.S. corporate tax changes, the company posted a fourth-quarter net loss of $3.87 billion.\nQuarterly sales of hepatitis C drugs totaled $1.5 billion, down from $3.2 billion a year earlier, but in line with analysts' forecasts. The company's antiviral and HIV drug sales rose to $3.7 billion from $3.4 billion.\nShares of Gilead, which rose 2.5 percent to close at $80.38 in regular trading on the Nasdaq, were down 3 percent at $78 after hours.", "external_links": [], "published": "2018-02-07T00:30:00.000+02:00", "crawled": "2018-02-07T00:30:47.048+02:00", "highlightTitle": ""}